{"entity":{"id":"nct05927142","kind":"trial","name":"Combining Anti-PD-L1 Immune Checkpoint Inhibitor Durvalumab With TLR-3 Agonist Rintatolimod in Patients With Metastatic Pancreatic Ductal Adenocarcinoma for The","aka":["DURIPANC"],"tldr":"A phase 1/2 trial of durvalumab in pancreatic cancer, run by Joachim Aerts, MD PhD, now recruiting.","summary":"Combining Anti-PD-L1 Immune Checkpoint Inhibitor Durvalumab With TLR-3 Agonist Rintatolimod in Patients With Metastatic Pancreatic Ductal Adenocarcinoma for Therapy Efficacy is a phase 1/2, interventional study registered as NCT05927142 by Joachim Aerts, MD PhD, with a registry enrolment figure of 43 participants, started 2024-01-09 and due to reach its primary completion in 2026-04. Interventions recorded: Durvalumab; Rintatolimod. Conditions listed: Metastatic Pancreatic Cancer. Primary outcome: Phase Ib: Determine safety of combination therapy with durvalumab and rintatolimod; Phase II: Determine the clinical benefit rate of combination therapy with durvalumab and rintatolimod.. Pancreatic eligibility wording from the registry: \"* Histologically or cytologically (Bethesda 5 or 6) confirmed metastatic pancreatic cancer, as indicated by a definite cytology/histology report\". Sites: Netherlands. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-24","links":[{"label":"ClinicalTrials.gov NCT05927142","url":"https://clinicaltrials.gov/study/NCT05927142"}],"tags":["ctgov-ingest","pancreatic-deep-dive"],"related":[],"cancers":["metastatic-pdac"],"sections":[],"technologies":["checkpoint-inhibitor"],"targets":[],"drugs":["durvalumab"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT05927142","phase":"1/2","setting":"Combining Anti-PD-L1 Immune Checkpoint Inhibitor Durvalumab With TLR-3 Agonist Rintatolimod in Patients With Metastatic Pancreatic Ductal Adenocarcinoma for Therapy Efficacy","sponsor":"Joachim Aerts, MD PhD","enrolled":43,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct05927142/","neighbours":{"cancer":[{"id":"metastatic-pdac","kind":"cancer","name":"Metastatic pancreatic ductal adenocarcinoma","route":"/cancers/metastatic-pdac/"}],"technology":[{"id":"checkpoint-inhibitor","kind":"technology","name":"Immune checkpoint inhibitors","route":"/technologies/checkpoint-inhibitor/"}],"drug":[{"id":"durvalumab","kind":"drug","name":"Durvalumab","route":"/drugs/durvalumab/"}],"term":[{"id":"pancreatic-trials-open-today","kind":"term","name":"Pancreatic cancer trials open today (registry snapshot and UK sites)","route":"/terms/pancreatic-trials-open-today/"}]}}